SCHEMBL5185993

SCHEMBL5185993

Brc1ccc(N2CCN(CCNc3nc4ccccc4s3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC27A1 Q6PCB7 1/20 0.52
HTR1A P08908 7/20 0.50
HTR2A P28223 7/20 0.50
SLC6A4 P31645 7/20 0.50
DRD2 P14416 7/20 0.50
HTR7 P34969 6/20 0.50
DRD3 P35462 5/20 0.50
HTR2C P28335 4/20 0.50
DRD1 P21728 2/20 0.50
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HRH1 P35367 3/20 0.47
DRD4 P21917 1/20 0.47
ILK Q13418 2/20 0.46
SLC6A3 Q01959 1/20 0.45
LRRK2 Q5S007 1/20 0.45
QPCT Q16769 1/20 0.45
IDO1 P14902 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5185914 0.91 HTR1A (0.56) SLC27A1HTR1AHTR2ASLC6A4DRD2
SCHEMBL5185915 0.89 SLC6A4 (0.64) SLC27A1HTR1AHTR2ASLC6A4DRD2
SCHEMBL7523236 0.89 SLC27A1 (0.66) SLC27A1HTR1AHTR2ASLC6A4DRD2
Hydrochloric Acid SCHEMBL7522315 0.88 SLC6A4 (0.63) SLC27A1HTR1AHTR2ASLC6A4DRD2
Hydrochloric Acid SCHEMBL7523122 0.88 SLC27A1 (0.64) SLC27A1HTR1AHTR2ASLC6A4DRD2
SCHEMBL7518692 0.85 SLC27A1 (0.48) SLC27A1HTR1AHTR2ASLC6A4DRD2
SCHEMBL5185969 0.84 DRD2 (0.59) SLC27A1HTR1AHTR2ASLC6A4DRD2
SCHEMBL5185901 0.84 DRD2 (0.50) SLC27A1HTR1AHTR2ASLC6A4DRD2
Fumaric Acid SCHEMBL7529655 0.83 DRD2 (0.56) SLC27A1HTR1AHTR2ASLC6A4DRD2
Fumaric Acid SCHEMBL7529648 0.83 DRD2 (0.56) SLC27A1HTR1AHTR2ASLC6A4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1325917-B1 Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands JANSSEN PHARMACEUTICA NV (BE) 2007-01-03 EP claimed
EP-0912533-B1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2004-09-29 EP claimed
EP-1325917-A1 Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-09 EP claimed
EP-0912533-A1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-05-06 EP claimed
WO-1997043271-A1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1997-11-20 WO claimed
EP-1325917-B1 Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands JANSSEN PHARMACEUTICA NV (BE) 2007-01-03 EP disclosed
EP-0912533-B1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2004-09-29 EP disclosed
EP-1325917-A1 Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-09 EP disclosed
US-6224849-B1 Alkylaminobenzothiazole and-benzoxazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2001-05-01 US disclosed
US-6103725-A HIGH AFFINITY TO THE DOPAMINE D4 RECEPTOR; ANTAGONISTS; ANTIPSYCHOTIC AGENTS, E.G. SCHIZOPHRENIA, WITH REDUCED SIDE-EFFECTS; ANTIPSYCHOTIC AGENTS; ANXIOLYTIC AND ANTIEMETIC AGENTS; MOTORIC FUNCTIONS, ADDICTION, SLEEP, FEEDING JANSSEN PHARMACEUTICA, N.V. (BE) 2000-08-15 US disclosed
EP-0912533-A1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-05-06 EP disclosed
WO-1997043271-A1 ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1997-11-20 WO disclosed